Skip to main content
    O

    Orchestra BioMed Holdings Inc. (OBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.12
    -0.13 (-1.79%)

    Market Cap: $570.61M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Orchestra BioMed Holdings Inc. (OBIO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Orchestra BioMed Holdings reported revenue of $33.48M for the fiscal year ended Dec 31, 2025, up 1169.2% from the year before. That year, net income was -$52.70M with a net margin of -157.4%, operating cash flow was -$48.96M and free cash flow was -$49.45M. The quarter ended Sep 30, 2026 had revenue of $91.00K and net income of -$18.75M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $5.70M, a compound annual rate of 42.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$33.48M+1169.2%99.4%-154.7%-157.4%
    Dec 2024$2.64M-4.4%92.3%-2437.5%-2313.3%
    Dec 2023$2.76M-21.9%93.3%-1866.2%-1779.7%
    Dec 2022$3.53MN/A94.0%-924.3%-951.3%
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$5.70MN/A97.5%-328.8%-374.5%
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$33.48M$2.64M$2.76M$3.53M$0$5.70M
    Cost of revenue$190.00K$204.00K$186.00K$211.00K$0$145.00K
    Gross profit$33.29M$2.43M$2.57M$3.32M$0$5.56M
    Research and development$58.19M$42.80M$33.82M$21.95M$0$13.48M
    Operating income-$51.81M-$64.30M-$51.51M-$32.66M-$394.76K-$18.75M
    Net income-$52.70M-$61.02M-$49.12M-$33.61M-$378.75K-$21.36M
    EBITDAN/AN/AN/AN/A-$394.76K-$18.61M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$91.00K$88.00K$110.00K$30.92M$861.00K$836.00K$868.00K$253.00K$987.00K$778.00K$620.00K$262.00K
    Gross profit$63.00K$63.00K$78.00K$30.87M$812.00K$790.00K$824.00K$195.00K$919.00K$734.00K$586.00K$215.00K
    Operating income-$23.30M-$22.36M-$22.08M$6.75M-$20.31M-$19.33M-$18.92M-$16.68M-$16.34M-$16.86M-$14.42M-$12.48M
    Net income-$18.75M-$23.75M-$20.69M$6.25M-$20.83M-$19.36M-$18.75M-$16.16M-$15.43M-$15.98M-$13.46M-$12.82M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $15.02M by $19.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$114.86M$76.17M$95.21M$95.57M$161.82M$162.16M
    Current assets$107.91M$69.17M$89.11M$84.69M$1.80M$2.15M
    Cash and equivalents$34.69M$22.26M$30.56M$19.78M$1.75M$2.03M
    Total liabilities$51.48M$43.22M$27.17M$43.04M$5.77M$5.72M
    Short-term debt$751.00K$550.00K$649.00K$697.00K$2.00M$4.00M
    Long-term debt$14.27M$14.29M$0$9.49M$3.67M$5.46M
    Shareholder equity$53.57M$32.96M$68.04M$52.53M-$3.94M-$3.56M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$107.74M$115.70M$100.66M$114.86M$104.81M$42.83M$59.05M$76.17M$75.32M$72.38M$82.63M$95.21M
    Total liabilities$88.99M$86.28M$49.69M$51.48M$61.07M$42.53M$42.19M$43.22M$29.10M$28.26M$25.44M$27.17M
    Cash and equivalents$27.76M$20.47M$28.37M$34.69M$42.01M$18.75M$18.35M$22.26M$25.61M$23.71M$23.32M$30.56M
    Shareholder equity$7.78M$19.32M$41.19M$63.38M$43.74M$295.00K$16.86M$32.96M$46.22M$44.13M$57.19M$68.04M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$48.96M-$50.56M-$46.13M-$29.29M-$272.36K-$26.18M
    Capital expenditures$489.00K$289.00K$78.00K$591.00K$274.00K$539.00K
    Free cash flow-$49.45M-$50.85M-$46.20M-$29.88M-$546.36K-$26.72M
    Share repurchasesN/AN/AN/A$10.00KN/AN/A
    Investing cash flow-$26.94M$13.09M$10.69M-$64.12M$0$26.97M
    Financing cash flow$88.33M$29.17M$46.22M$103.26M$0$10.00M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$19.54M-$19.33M-$22.17M-$2.27M-$14.55M-$15.53M-$16.62M-$13.54M-$13.70M-$10.21M-$13.11M-$10.97M
    Capital expenditures$398.00K$254.00K$184.00K$33.00K$310.00K$34.00K$112.00K$106.00K$68.00K$107.00K$8.00K$3.00K
    Free cash flow-$19.94M-$19.59M-$22.35M-$2.30M-$14.86M-$15.56M-$16.73M-$13.64M-$13.77M-$10.31M-$13.12M-$10.98M
    Last 12 quarters

    Frequently Asked Questions About OBIO

    What is Orchestra BioMed Holdings' annual revenue?

    Orchestra BioMed Holdings reported revenue of $33.48M for the fiscal year ended Dec 31, 2025.

    How fast is Orchestra BioMed Holdings' revenue growing?

    Revenue was up 1169.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 111.6%.

    Is Orchestra BioMed Holdings profitable?

    No. Orchestra BioMed Holdings reported net income of -$52.70M for the fiscal year ended Dec 31, 2025, with a net margin of -157.4%.

    How much free cash flow does OBIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.96M minus capital expenditures of $489.00K produced free cash flow of -$49.45M.

    How much debt does Orchestra BioMed Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $14.27M, short-term debt of $751.00K and cash and equivalents of $34.69M.